Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 24'th Feb 2021
Sangamo (SGMO) delivered earnings and revenue surprises of -61.11% and -31.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Hea
7 CRISPR Stocks for the Future of Medicine
06:12pm, Friday, 15'th Jan 2021
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
04:10pm, Wednesday, 06'th Jan 2021
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new o
Sangamo: 'Good Companies Get Bought, Not Sold'
08:58am, Wednesday, 23'rd Dec 2020
Sangamo: 'Good Companies Get Bought, Not Sold'
Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5%
12:02pm, Tuesday, 15'th Dec 2020
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase
Genomic Medicine: Slowly Moving To All At Once
08:50pm, Monday, 16'th Nov 2020
Gene regulation targeted at RNA or DNA has enormous potential for previously intractable nervous system disorders. Allele-specific gene regulation is a more precise approach targeting only the mutant
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript
12:21am, Thursday, 05'th Nov 2020
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript
